STOCK TITAN

Serina Therapeutics (SER) director granted 15,250 stock options at $1.98 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Serina Therapeutics, Inc. director Marshall Richard Peter reported receiving a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036.

According to the filing, the options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options directly from this award.

Positive

  • None.

Negative

  • None.
Insider Marshall Richard Peter
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 15,250 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 15,250 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 15,250 options Grant to director on June 17, 2026
Exercise price $1.98 per share Stock option strike price
Expiration date June 17, 2036 Option term for this grant
Underlying shares 15,250 shares Common stock underlying granted options
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "1.9800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-17T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting financial
"the day before the next Annual Meeting or (ii) the one-year anniversary"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
grant date financial
"the one-year anniversary of the grant date, subject to the Reporting Person's continued service"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marshall Richard Peter

(Last)(First)(Middle)
601 GENOME WAY, SUITE 2001

(Street)
HUNTSVILLE ALABAMA 35806

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.9806/17/2026A15,250 (1)06/17/2036Common Stock15,250$015,250D
Explanation of Responses:
1. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Remarks:
/s/ Steven Ledger, Attorney in Fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Serina Therapeutics (SER) director Marshall Richard Peter report on this Form 4?

He reported a grant of stock options covering 15,250 shares of Serina Therapeutics common stock. The options were awarded at an exercise price of $1.98 per share and represent compensation rather than an open-market purchase or sale of existing shares.

What are the key terms of the Serina Therapeutics (SER) stock options granted to Marshall Richard Peter?

The grant covers 15,250 options at $1.98 per share, expiring on June 17, 2036. These options give him the right to buy Serina Therapeutics common stock at that price if and when they vest and are exercised.

When do Marshall Richard Peter’s Serina Therapeutics (SER) stock options vest?

The options vest based on time and service, on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant. Vesting is conditioned on his continued service with the company.

Is this Serina Therapeutics (SER) Form 4 a stock purchase or sale by the director?

No, it reflects a compensation-related stock option grant, not an open-market trade. The options were granted at an exercise price of $1.98 and involve no cash paid or received until any future exercise of the options.

How many Serina Therapeutics (SER) stock options does Marshall Richard Peter hold after this grant?

After this reported grant, he holds 15,250 stock options from this award. These options relate to 15,250 underlying shares of common stock and will remain exercisable until their June 17, 2036 expiration, subject to vesting conditions.